TY - JOUR
T1 - Congenital Familial Transient Hypothyroidism Secondary to Transplacental Throtropin-Blocking Autoantibodies
AU - Francis, Gary
AU - Riley, William
PY - 1987/10
Y1 - 1987/10
N2 - Three patients demonstrated transient neonatal hypothyroidism, presumably secondary to maternally derived thyrotropin (TSH)–blocking antibodies. Although transient, this disorder might not have been benign in the first child, who exhibited significant developmental delay. A thyroid scan was not helpful in making this diagnosis. Although uncommon, this disorder should be suspected in infants with a maternal history of autoimmune autoimmune thyroid disease, multiple siblings with congenital hypothyroidism, or a clinical course characterized by continually suppressed TSH levels, despite low doses of levothyroxine sodium replacement. Measurement of TSH-blocking antibodies may be used in the diagnosis of transient neonatal hypothyroidism at birth and is becoming more readily available from reference laboratories. Once diagnosed, the patient may then be prepared for monitored withdrawal of levothyroxine replacement therapy at 2 to 3 years of age and Will not be committed to lifelong replacement therapy.
AB - Three patients demonstrated transient neonatal hypothyroidism, presumably secondary to maternally derived thyrotropin (TSH)–blocking antibodies. Although transient, this disorder might not have been benign in the first child, who exhibited significant developmental delay. A thyroid scan was not helpful in making this diagnosis. Although uncommon, this disorder should be suspected in infants with a maternal history of autoimmune autoimmune thyroid disease, multiple siblings with congenital hypothyroidism, or a clinical course characterized by continually suppressed TSH levels, despite low doses of levothyroxine sodium replacement. Measurement of TSH-blocking antibodies may be used in the diagnosis of transient neonatal hypothyroidism at birth and is becoming more readily available from reference laboratories. Once diagnosed, the patient may then be prepared for monitored withdrawal of levothyroxine replacement therapy at 2 to 3 years of age and Will not be committed to lifelong replacement therapy.
UR - http://www.scopus.com/inward/record.url?scp=0023587765&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0023587765&partnerID=8YFLogxK
U2 - 10.1001/archpedi.1987.04460100059025
DO - 10.1001/archpedi.1987.04460100059025
M3 - Article
C2 - 3630993
AN - SCOPUS:0023587765
SN - 2168-6203
VL - 141
SP - 1081
EP - 1083
JO - A.M.A. American journal of diseases of children
JF - A.M.A. American journal of diseases of children
IS - 10
ER -